Metformin prevents obesity-promoted pancreatic cancer development in the conditional KrasG12D mouse model
Objectives Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with virtually no efficacious treatments. Chronic conditions such as obesity and type-2 diabetes are known risk factors, thus making PDAC amenable for preventive strategies. Metformin, a widely used anti-diabetic drug shown to improve metabolic dysfunction, has been linked epidemiologically with reduced incidence, recurrence and mortality of cancer in diabetic patients. However, the efficacy and mechanisms of metformin in obesity-promoted PDAC are much less known.
Source: Pancreatology - Category: Gastroenterology Authors: Hui-Hua Chang, James Sinnett-Smith, O. Joe Hines, Enrique Rozengurt, Guido Eibl Tags: 7. Experimental pancreatic cancer II Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Epidemiology | Fortamet | Metformin | Obesity | Pancreas | Pancreatic Cancer